Imaging amyloid deposition in lewy body diseases

Neurology

Volumn 71, Issue 12, 2008, Pages 903-910

  Gomperts, S N ^a,b   Rentz, D M ^b,c   Moran, E ^a   Becker, J A ^a   Locascio, J J ^a,b,d   Klunk, W E ^e   Mathis, C A ^e   Elmaleh, D R ^a,b   Shoup, T ^a   Fischman, A J ^a   Hyman, B T ^a,b   Growdon, J H ^a,b   Johnson, K A ^a,b,c,f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f Division of Nuclear Medicine and Molecular Imaging   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; LEVODOPA; 2 (4' (METHYLAMINO)PHENYL) 6 HYDROXYBENZOTHIAZOLE; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; DIAGNOSTIC AGENT; THIAZOLE DERIVATIVE;

AGED; ARTICLE; BRAIN CORTEX; CINGULATE GYRUS; CLINICAL ARTICLE; CLINICAL EVALUATION; COGNITION; CONTROLLED STUDY; DISTRIBUTION VOLUME; FEMALE; HUMAN; LEWY BODY; MALE; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; OCCIPITAL LOBE; PARIETAL LOBE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; BRAIN; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; METABOLISM; MIDDLE AGED; MOVEMENT (PHYSIOLOGY); PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; SCINTISCANNING; TISSUE DISTRIBUTION;

AGED; AMYLOID BETA-PROTEIN; ANILINE COMPOUNDS; BRAIN; COGNITION; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; MOVEMENT; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES; TISSUE DISTRIBUTION;

EID: 54049100454     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000326146.60732.d6     Document Type: Article

References (41)

1. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707.
2. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
3. Lippa CF, Duda JE, Grossman M, et al. DLB/PDD Working Group. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007;68:812-819.
4. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 2001;102: 355-363.
5. Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407-411.
6. Mattila PM, Röyttä M, Torikka H, Dickson DW, Rinne JO. Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol 1998; 95:576-582.
7. McKeith IG, Burn D. Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. In: De-Kosky ST, ed. Neurologic Clinics. Philadelphia: WB Saunders, 2000:865-883.
8. Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004;17:137-145.
9. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-148.
10. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
11. McKhann G, Drachman DA, Folstein M, Katzman R, Price DL, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
12. Lang A, Fahn S. Assessment of Parkinson's disease. In: Munstat TL, ed. Quantification of Neurologic Deficit. Boston: Butterworths, 1989:285-309.
13. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004;62:181-187.
14. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
15. Grober E, Buschke H, Crystal H, et al. Screening for dementia by memory testing. Neurology 1988;38:900-903.
16. Mathis CA, Wang Y, Holt DP, et al. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-2754.
17. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-840.
18. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh Compound B amyloid imag- ing PET studies: a comparative analysis. J Nucl Med 2005; 46:1959-1972.
19. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PiB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452.
20. Archer HA, Edison P, Brooks DJ, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an (11)C-PiB positron emission tomography study. Ann Neurol 2006; 60:145-147.
21. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A/342 in humans. Ann Neurol 2006;59:512-519.
22. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62:229-234.
23. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273-289.
24. Friston KJ, Holmes AP, Worsley KJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995;2:189-210.
25. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68:1718-1725.
26. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007;64:431-434.
27. Maetzler W, Reimold M, Liepelt I, et al. [11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008;39: 1027-1033.
28. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130: 2837-2844.
29. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999;45:358-368.
30. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006;66: 1837-1844.
31. Kemppainen NM, Aalto S, Karrasch M, et al. Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol 2008; 63:112-118.
32. Braak H, Braak E. Cognitive impairment in Parkinson's disease: amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex. J Neural Transm Park Dis Dement Sect 1990;2:45-57.
33. Lockhart A, Lamb JR, Osredkar T, et al. PiB is a nonspecific imaging marker of amyloid-beta (A/3) peptide-related cerebral amyloidosis. Brain 2007;130:2607-2615.
34. Jellinger KA. Prevalence of vascular lesions in dementia with Lewy bodies: a postmortem study. J Neural Transm 2003;110:771-778.
35. Mastaglia FL, Johnsen RD, Byrnes ML, Kakulas BA. Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson's disease. Mov Disord 2003;18:81-86.
36. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4′- methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003;23:2086-2092.
37. Fodero-Tavoletti MT, Smith DP, McLean CA, et al. In vitro characterization of Pittsburgh Compound-B binding to Lewy bodies. J Neurosci 2007;27:10365-10371.
38. Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PiB and [18F]FDG PET study. Neurology 2007;68:501-508.
39. Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol 2007;14:1357-1362.
40. Jellinger KA, Attems J. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol 2006;112:253-260.
41. Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007;27: 6174-6184.